BCIwiki (bciwiki.com) — NeuroXess reported on July 8, 2026, that its implantable brain-computer interface (BCI) system for hand motor function compensation began a Good Clinical Practice (GCP) registration clinical trial that day at Huashan Hospital, Fudan University, in China. The company describes the system as fully implantable, fully wireless and fully functional. This marks the start of a device registration clinical trial, not regulatory approval for market entry.
According to NeuroXess, Professor Mao Ying's team at Huashan Hospital, Fudan University, serves as the principal investigator team. The trial aims to evaluate safety and efficacy for upper limb function compensation in people with tetraplegia caused by cervical spinal cord injury. The multicenter study involves 15 Grade III Class A hospitals, and its data will support a Class III medical device registration application to China's National Medical Products Administration (NMPA). Safety and efficacy are evaluation objectives, not outcomes established by the trial's launch.
The company says the system places flexible electrodes beneath the dura on the cortical surface without entering brain tissue. Its split design positions the battery, wireless data transmission and wireless charging units under the skin of the chest. NeuroXess says this arrangement is intended to keep those heat-generating units away from the brain. These statements describe the company's design and rationale; they do not replace clinical safety evaluation.